A Beta-only IL-2 ImmunoTherapY Study

Clinical trial NCT05086692 · RECRUITING

Trial details

NCT number: NCT05086692
Sponsor: Medicenna Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Unresectable Solid Tumor Clear Cell Renal Cell Carcinoma Triple Negative Breast Cancer Non-Small Cell Lung Cancer Squamous Non-Small Cell Lung Cancer Non-squamous Colorectal Cancer (MSI-H)Gastric Cancer Cervical Cancer Basal Cell Carcinoma Bladder Cancer Merkel Cell Carcinoma

Start date: 2021-08-27
Primary completion: 2026-06-30
Enrollment: 115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.